Nachrichten zur Illumina Inc. Aktie

Illumina expects full-year sales from core segment to decline on biotech funding crunch By Reuters

Illumina expects full-year sales from core segment to decline on biotech funding crunch…

Massive Kursverluste für das Wertpapier von Illumina (109,14 €)

Keinen Grund zur Freude haben die Investoren von Illumina : Der Titel verbilligt sich am Freitag deutlich. Der Anteilsschein von…

Illumina-Aktie gewinnt 4,35 Prozent (111,6930 €)

Die Aktie von Illumina zählt am Donnerstag zu den großen Gewinnern an der Börse. Das Wertpapier verteuert sich heute deutlich.…

Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet

The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after…

Analyst Report: Illumina Inc

…

Illumina: Citi erhöht Rating auf "buy" - Aktienanalyse

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von der Citigroup: Die Analysten der Citigroup stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN:…

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

By integrating Fluents unique technology with Illuminas (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a…

Global Cancer Diagnostics Market Size To Exceed USD 323.17 Billion By 2033 | CAGR of 8.71%

The Global Cancer Diagnostics Market Size was Valued at USD 140.25 Billion in 2023 and the Worldwide Cancer Diagnostics Market…

Gene-sequencing group Illumina sees $1.47 bn Q2 impairment charge linked to Grail By Investing.com

Gene-sequencing group Illumina sees $1.47 bn Q2 impairment charge linked to Grail…

Illumina to take $1.47 billion goodwill impairment charge related to Grail in Q2 By Reuters

Illumina to take $1.47 billion goodwill impairment charge related to Grail in Q2…

Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2

Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to…

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…

Grail bets big on flagship cancer test after spin-off from Illumina

U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out…

Grail bets big on flagship cancer test after spin-off from Illumina By Reuters

Grail bets big on flagship cancer test after spin-off from Illumina…

Global Nucleic Acid Isolation & Purification Market Size To Exceed USD 12.3 Billion by 2033 | CAGR Of 8.38%

The Global Nucleic Acid Isolation & Purification Market Size was Valued at USD 5.5 Billion in 2023 and the Worldwide…

Illumina: Neues Kursziel

New York (www.aktiencheck.de) - Rating-Update: Guggenheim Securities stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN)…

Global Companion Diagnostics Market Size To Exceed USD 23.12 Billion By 2033 | CAGR Of 12.50%

The Global Companion Diagnostics Market Size was Valued at USD 7.12 Billion in 2023 and the Worldwide Companion Diagnostics Market…

Kurs von Illumina bricht ein (100,5042 €)

Die Aktie von Illumina zählt am Mittwoch zu den großen Verlierern am Aktienmarkt. Das Papier verbilligt sich heute deutlich. Mit…

Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch

One of the standout features of Illuminas (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.…

Aktienmarkt: Aktie von Illumina tritt auf der Stelle (102,0607 €)

Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Illumina . Das Papier notiert gegenwärtig bei 109,80 US-Dollar. Kaum verändert im…

Illumina: Dauerhafte Wachstumsstorys sollten belohnt werden - Aktienanalyse

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von Jefferies & Co: Die Analysten von Jefferies & Co nehmen die Coverage der Aktie von…

Illumina board approves spinoff of GRAIL

…

Illumina to spin off Grail in June

Illumina , a maker of gene sequencing machines, said on Monday it expected to spin off cancer test maker Grail…

Illumina to spin off Grail in June By Reuters

Illumina to spin off Grail in June…

Illumina, Inc. (ILMN) Bernstein Strategic Decisions Conference (Transcript)

…

Aktie von Illumina an der Börse auf der Verliererseite: Börsenkurs fällt deutlich (94,1776 €)

An der US-amerikanischen Börse fällt zur Stunde die Illumina-Aktie negativ auf. Das Papier verbilligt sich am Mittwoch deutlich. Zu den…

Global Precision Oncology Market Size To Exceed USA 260.5 Billion By 2033 | CAGR Of 10.21%

The Global Precision Oncology Market Size was Valued at USD 98.5 Billion in 2023 and the Worldwide Precision Oncology Market…

The Zacks Analyst Blog Highlights Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina

Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina are included in this Analyst Blog.…

Illumina, Inc. (ILMN) RBC Capital Markets Global Healthcare (Transcript)

…

Illumina shares gain 4% on upbeat RBC comments By Investing.com

Illumina shares gain 4% on upbeat RBC comments…

Illumina: Kursziel gesenkt

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten der Scotiabank stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol:…

Illumina, Inc. (ILMN) Q1 2024 Earnings Call Transcript

…

Illumina reaffirms annual revenue forecast over continued sluggish demand By Reuters

Illumina reaffirms annual revenue forecast over continued sluggish demand…

Illumina earnings beat by $0.05, revenue topped estimates By Investing.com

Illumina earnings beat by $0.05, revenue topped estimates…

Aktie von Illumina heute am Aktienmarkt gefragt (116,9609 €)

Im Plus liegt zur Stunde die Illumina-Aktie . Zuletzt zahlten Investoren für das Wertpapier 125,34 US-Dollar. Ein Wertanstieg von 2,50…

Genomics Luminary and former Illumina Executive Bob Kain Joins Single Technologies as an Advisor

Stockholm, Sweden, 23 April 2024 – Renowned genomics pioneer, Bob Kain, has joined Single Technologies as an advisor to support…

Illumina: EU-Genehmigung des Verkaufsplans für Grail - Aktienanalyse

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von Evercore ISI: Vijay Kumar, Analyst von Evercore ISI, nimmt in einer aktuellen Aktienanalyse die Aktie…

Kurs fällt um 3,75 Prozent: Illumina-Aktie unter Druck (115,0253 €)

An der US-amerikanischen Börse fällt gegenwärtig die Illumina-Aktie negativ auf. Das Papier verliert deutlich an Wert. Mit einem Kurssturz von…

Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%

The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is…

EU approves Illuminas plan to divest cancer test maker Grail By Reuters

EU approves Illuminas plan to divest cancer test maker Grail…

illumin Holdings Inc. announces date for First Quarter 2024 Financial and Operating Results

TORONTO, April 11, 2024 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising…

Illumina CFO steps down amid executive shakeup

…

Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by…

Illumina CFO Goswami to depart, Summit Therapeutics Dhingra named successor By Reuters

Illumina CFO Goswami to depart, Summit Therapeutics Dhingra named successor…

Illumina: Downgrade

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von OTR Global stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

EU court should back Illuminas appeal against EU review of Grail deal, court adviser says By Reuters

EU court should back Illuminas appeal against EU review of Grail deal, court adviser says…

Illumina shares fall as Ichan reportedly abandons second proxy contest By Investing.com

Illumina shares fall as Ichan reportedly abandons second proxy contest…

Exclusive-Icahn drops Illumina board challenge threat, sources say

Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illuminas board, sparing the U.S. gene…

Exclusive-Icahn drops Illumina board challenge threat, sources say By Reuters

Exclusive-Icahn drops Illumina board challenge threat, sources say…

Illuminas Turnaround Play: Betting On NovaSeq X Amidst Rising Competitive Tides

…